The effect of different doses of glibenclamide on blood glucose and islet volume in diabetic rats

Document Type : Original article

Authors

1 MSc, Department of Anatomical Sciences and Cell Biology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 MSc, Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

3 Assistant Professor, Department of Anatomical Sciences, MUMS

Abstract

Introduction:Diabetes decreases the quality of life and can impair the function of several organs, including eyes, kidneys, and heart. Glibenclamide is a second-line drug for the management of diabetes. The purpose of this study was to determine the effect of different doses of glibenclamide on blood glucose and islet volume in an animal model.
Materials and Methods:This experimental study was conducted on 30 adult Wistar rats. The animals were randomly divided into 5 groups of sham control, diabetic control, 2.5 mg/kg glibenclamide, 5 mg/kg glibenclamide, and 10 mg/kg glibenclamide. Diabetes was induced by the intraperitoneal injection of 35 mg/kg streptozotocin with a high-fat diet. The data were analyzed in SPSS software (version 17) using one-way ANOVA and Tukey's post hoc test. P-value less than 0.05 was considered statistically significant.
Results:Except for the glibenclamide group receiving 2.5 mg/kg, other experimental groups showed a significant decrease in blood glucose level as compared to the diabetic control group (P=0.00). Comparison of data among different groups showed that diabetes significantly reduced the islet volume (P=0.00). Although all experimental groups showed an increase in the islet volume as compared to the diabetic control group, none of these increases were significant (P> 0.05).
Conclusion:As the findings indicated, the treatment of diabetic rats with glibenclamide resulted in the significant reduction of blood glucose level and elevation of the islet volume. These changes were appropriate at the doses of 5 and 10 mg/kg. Furthermore, the results revealed that with an increase in the dose of glibenclamide, no changes occurred in the extent of glibenclamide effect.

Keywords

References

1.     American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37(Suppl 1):S81-90.
2.     Ostergaard L, Mogensen UM, Bundgaard JS, Dahl A, Wang A, Torp-Pedersen C, et al. Duration and complications of diabetes mellitus and the associated risk of infective endocarditis. Int J Cardiol. 2019; 278:280-4.
3.     Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018; 379(7):
633-44.
4.     Eileen Dolan M. Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents. Adv Drug Deliv Rev. 1997; 26(2-3):105-18.
5.     Vivek K. Streptozotocin: an experimental tool in diabetes and alzheimer’s disease (A-Review). Int J Pharma Res Dev. 2010; 2(1):1-7.
6.     Rakeiten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin. Cancer Chemother Rep. 1963; 29:91-8.
7.     Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev. 1970; 22(4):485-518.
8.     Jin R, Jin Z, Cai H. Influence of electroacupuncture plus jasminoidia intervention on expression of OX-42 and nuclear factor-kappa B in hippocampus and amygdale in cerebral ischemia plus diabetes rats. Zhen Ci Yan Jiu. 2014; 39(4):305-12.
9.     Holmes A, Coppey LJ, Davidson EP, Yorek MA. Rat models of diet-induced obesity and high fat/low dose streptozotocin type 2 diabetes: effect of reversal of high fat diet compared to treatment with enalapril or menhaden oil on glucose utilization and neuropathic endpoints. J Diabetes Res. 2015; 2015:307285.
10.  Groop L, Groop PH, Stenman S, Saloranta C, Tötterman KJ, Fyhrquist F, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care. 1987; 10(6):671-8.
11.  Meier J, Gallwitz B, Schmidt W, Mügge A, Nauck M. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart. 2004; 90(1):9-12.
12.  Zhang BB, Moller DE. New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol. 2000; 4(4):461-7.
13.  Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Boupaijit K, Panpuwong N, et al. Cost of diabetes and its complications in Thailand: a complete picture of economic burden. Health Soc Care Community. 2011; 19(3):289-98.
14.  Autore G, Capasso F, De Fusco R, Fasulo M, Lembo M, Mascolo N, et al. Antipyretic and antibacterial actions of Teucrium polium (L.). Pharmacol Res Commun. 1984; 16(1):21-9.
15.  Marble A. Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents? Drugs. 1971; 1(2):109-15.
16.  Ashcroft F. KATP channels and insulin secretion: a key role in health and disease. Biochem Soc Trans. 2006; 34(Pt 2):243-6.
17.  Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature. 2006; 440(7083):470-6.
18.  Mirbadalzadeh R, Shirdel Z. Antihyperglycemic and antihyperlipidemic effects of Cornus mas extract in diabetic rats compared with glibenclamide. Elixir (Hormo & Signal). 2012; 47:8969-72.
19.  Simard JM, Woo SK, Schwartzbauer GT, Gerzanich V. Sulfonylurea receptor 1 in central nervous system injury: a focused review. J Cereb Blood Flow Metab. 2012; 32(9):1699-717.
20.  Sarkarizi HK, Sazegar G, Rajabzadeh A. Effect of hydro-alcoholic teucrium polium L. extract and glibenclamide administration on blood glucose and lipid profile levels in streptozotocin-induced diabetic rats. Clin Res. 2015; 1(2):38-45.
21.  Ashrafihelan J, Yazdanparast R, Esmaeili M, Nowrozi M. A pathologic study on changes of pancreas, liver and kidney due to Teucrium polium extract in streptozotocin induced-diabetic rats. Pharm Sci. 2010; 16(1):11-20.
22.  Erejuwa OO, Sulaiman SA, Wahab MS, Sirajudeen KN, Salleh MS, Gurtu S. Glibenclamide or metformin combined with honey improves glycemic control in streptozotocin-induced diabetic rats. Int J Biol Sci. 2011; 7(2):244.
Navid No
Volume 21, Issue 68
March 2019
Pages 10-18

Files

Share

How to cite

Statistics